This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): Fc-CD68
Description: COR-2 is a recombinant protein which specifically interferes with the generation of foam cells and inhibits the cellular uptake of cholesterol by binding to oxidized LDL (oxLDL), and thereby prevents oxLDL uptake to foam cells in atherosclerotic plaques, and reduced local inflammation of the vascular wall.
Deal Structure: In June 2012, Janssen announced it completed the acquisition of CorImmun for an undisclosed upfront payment and a contingent future clinical milestone payment.
Additional information available to subscribers only: